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Abstract 
An HLA-A2.1 transgenic rabbit /Cottontail rabbit papillomavirus (CRPV) infection model has been 
reported previously. In this study, we incorporated online MHCI epitope prediction software and  HLA-A2.1 
transgenic mouse and rabbit systems together to demonstrate an efficient way to identify and test immunogenicity of 
two HLA-A2.1 restricted epitopes from CRPVE1 (161-169 LLFRQAHSV and 303-311 MLQEKPFQL). Both 
epitopes were able to induce specific cytotoxic CD8 T cells in HLA-A2.1 mice and rabbits after peptide and DNA 
immunization and in vitro stimulation respectively. Using an epitope DNA vaccination method, we achieved partial 
and complete protection against CRPV DNA challenge by CRPVE1/161-169 and CRPVE1/303-311 respectively in 
HLA-A2.1 transgenic outbred rabbits. CRPVE1/303-311 also showed strong and specific therapeutic effects in 
CRPV-infected HLA-A2.1 transgenic outbred rabbits. Interestingly, epitope CRPVE1/303-311 (but not E1/161-169) 
showed strong protective immunity in non-transgenic EIII/JC inbred (but not outbred) NZW rabbits. Our data 
demonstrates an efficient way to identify HLA-A2.1 restricted epitopes for the development of prophylactic and 
therapeutic vaccines. 
© 2009 Elsevier B.V.    
PACS: Type pacs here, separated by semicolons ;  
Keywords: Epitope DNA vaccine, A2, transgenic mouse, transgenic rabbit, CRPV 
1. Introduction 
HLA-A2.1 is a common human MHCI molecule among the Caucasian population.  Using an HLA-A2.1 
transgenic mouse system, investigators have screened and identified HLA-A2.1 restricted epitopes from a variety of 
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pathogens in  the past two decades [1]. Online software makes the prediction of a potential HLA-A2.1 restricted 
epitope possible. Many well characterized epitopes have been tested for therapeutic effects for viral infection or 
tumor formation in the A2 mouse model [2, 3]. The disadvantage of the HLA-A2.1 mouse model is the limited 
susceptibility of the mouse to some human pathogens such as HTLV-1 and syphilis. As a result, it is difficult to 
predict the protective effects of these and other identified epitopes with this model system. In contrast, the rabbit is 
susceptible to these pathogens and thus provides an excellent host to test the immunogenicity of different targets. 
Therefore, we established an HLA-A2.1 transgenic rabbit model in an  attempt to compensate for  the limitations of  
the HLA-A2.1 transgenic mouse model [4, 5]. 
Human papillomaviruses are small DNA tumor viruses, some of which induce malignancy in genital, anal, 
oropharyngeal and also skin tissues. The viruses show species specificity and thus no animal model is available to 
study HPV infection in vivo [6]. In addition, no mouse papillomavirus model has been reported so far. We used the 
cottontail rabbit papillomavirus (CRPV) / rabbit model that mimics high-risk HPV infections in the  human 
population [7-9]. We have found that  CRPV genome can be modified extensively without losing the ability  to 
induce papillomas in rabbits [10]. These unique characteristics make it possible to test the specific immunity 
induced by an HLA-A2.1 restricted epitope DNA vaccine by embedding the corresponding epitope in the  CRPV 
genome [5].  
In previous studies, we used online MHCI epitope prediction software to screen five HLA-A2.1 restricted 
epitopes from CRPVE1 and to generate a multivalent epitope DNA vaccine [5]. This vaccine provided complete 
protection against CRPV infection with a single booster immunization [11]. We further observed that two of the five 
epitopes (CRPVE1/161-169 and CRPVE1/303-311) could stimulate specific CTLs in the HLA-A2.1 transgenic 
mouse system by direct peptide immunization. In the current study we have shown that these two epitopes provided 
strong and specific protective immunity against CRPV DNA infection in HLA-A2.1 transgenic rabbits with both 
outbred and EIII/JC inbred genetic backgrounds. Partial therapeutic immunity was also induced by CRPVE1/303-
311 epitope DNA vaccination in the HLA-A2.1 transgenic outbred rabbits. Immunization with the CRPVE1/303-
311 peptide failed to stimulate protective immunity in HLA-A2.1 transgenic outbred rabbits, however. Our data 
demonstrate a direct correlation between these two transgenic animal model systems showing that these systems can 
be combined to screen and test protective and therapeutic epitope vaccines in vivo.
2. Material and Methods 
2.1. Peptide immunization in HLA-A2.1 transgenic mice and rabbits 
CRPVE1/161-169 (LLFRQAHSV), CRPVE1/303-311(MLQEKPFQL) and HBV core T helper peptide 
(TPPAYRPPNAPIL) were synthesized in the core facility of Pennsylvania State University College of Medicine. 
CRPVE1/161-169 and CRPVE1/303-311 were diluted into 1×PBS buffer (4 mg/ml containing 5% DMSO). HBV 
core T helper peptide was diluted into 1×PBS buffer (5.6 mg/ml containing 5% DMSO). Each peptide was mixed 
with HBV core T helper peptide and incomplete Freund’s adjuvant (IFA) at a 1:1:2 ratio with a homogenizer until 
the mixture was emulsified [12]. Each mouse was injected with 50 μl of emulsion on both sides of the base of the 
tail. Two mice were used for each peptide immunization. The mice were immunized twice with 2-week intervals 
between injections. Spleens were harvested one week after the booster immunization. HLA-A2.1 transgenic and 
normal rabbits were immunized with 200 μl of emulsion subcutaneously for 4 times at 2 week intervals. One week 
after the final booster immunization, the rabbits were challenged with viral DNA on four back sites respectively as 
described previously [5].  
2.2. Tetramer binding assay 
 After two rounds of in vitro stimulations, the bulk CTLs from HLA-A2.1 transgenic mice or rabbits were 
labeled with CD8-FITC and then specific PE conjugated tetramers (synthesized by the tetramer core facility of the 
National Institute of Health). A two-color flow cytometry analysis was used for detecting specific tetramer binding 
CD8 T cells at the core facility of Pennsylvania State University College of Medicine[13]. 
2.3. Intracellular cytokine assay 
 Bulk mouse CTLs were cultured in triplicate wells of a 96-well plate with 1μM peptide (either E1 peptides 
or a reference peptide HIVGagP17/77-85) and 1μM Brefeldin A at 37 oC for 3-4 hours. The cells were then labeled 
with FITC conjugated anti-mouse CD8 and PE conjugated anti-mouse interferon gamma and analyzed by two-color 
flow cytometry at the core facility of Pennsylvania State University College of Medicine as described previously 
[5]. 
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2.4. Chromium release assay 
T2 cell cultures were labeled with chromium (300 μCi) overnight before the assay and then pulsed with 
peptides (CRPVE1/161-169 and CRPVE1/303-311) on the day of assay as target cells. In vitro stimulated mouse or 
rabbit CTLs were harvested and divided into triplet wells using Effector /Target ( E:T ) ratio as 30:1, 10:1. 3.3:1 and 
1:1. T2 pulsed CRPVE1/161-169 and T2 pulsed CRPVE1/303-311 were used as negative controls for mice and 
rabbits immunized with CRPVE1/303-311 and CRPVE1/161-169 respectively. Target cells were cultured with the 
CTLs at 37 oC for 4 hours. Supernatant from target cells cultured alone and target cells lysed with 5%SDS were 
counted as minimum and maximum release respectively. The chromium release was counted by a Gamma-counter 
and the specific killing was calculated using standard formula. 
2.5. HLA-A2.1 restricted epitope DNA vaccines and vaccination in rabbits 
HLA-A2.1 transgenic and non-transgenic rabbits were maintained in the animal facilities of the 
Pennsylvania State University College of Medicine. All animal care and handling procedures were approved by the 
Institutional Animal Care and Use Committee of the Pennsylvania State University College of Medicine. HLA-A2.1 
transgenic rabbits with outbred genetic background and EIII/JC inbred genetic background were used.   
CRPVE1/161-169 and CRPVE1/303-311 epitope DNA vaccines were designed as described previously 
[5]. An ubiquitin only (Ub3) or HPV16E7/82-90 epitope DNA vaccine was used as control for protective studies. 
Animals were immunized with CRPVE1/161-169, CRPVE1/303-311and a control DNA vaccine using the same 
strategy as described previously [5]. In brief, the epitope DNA vaccines were purified with the QIAGEN MaxiPrep 
kit and adjusted to final concentration of 1μg/1μl in 1× TE buffer and then precipitated onto 1.6μm-diameter gold 
micro particles at a ratio of 1μg of DNA/0.5mg of gold particles as described by the manufacturer (Bio-Rad, 
Hercules, California) [14]. Inner ear skin sites were shaved and swabbed with 70% ethanol, and then DNA/gold 
particles were bombarded onto these sites by a gene gun at 400 lb/in2 [14].  
For protective vaccination, groups of rabbits were immunized twice with CRPVE1/161-169, CRPVE1/303-
311 or a control DNA vaccine (Ub3 or HPV16E7/82-90) respectively according to our previously published 
methods  [5]. These animals were subsequently challenged with Hershey progressive CRPV DNA (identified as 
wild type CRPV, wtCRPV) and an E7 codon-modified DNA (identified as coCRPV) at four left and right back sites 
respectively (5μg construct/ site) at one week after the booster immunization . The rationale for additional challenge 
with coCRPV genomes was that these genomes grew more rapidly (Manuscript in preparation) and present a greater 
vaccine challenge for the immunized rabbits. 
For therapeutic experiments, rabbits were challenged with wtCRPV DNA and a wtCRPV DNA with 
E8ATGko mutant (16) at four left and right back sites respectively (5μg construct/ site).  The rationale for including 
the CRPVE8ATGko mutant papillomavirus in this study was that this latter genome produced slow-growing, small 
papillomas that could represent a smaller tumor burden for the therapeutic vaccine. Four weeks following infection, 
the rabbits were immunized with CRPVE1/161-169, CRPVE1/303-311 respectively 3 times at three-week intervals.  
2.6. Viral DNA challenge on rabbits and statistical analysis 
New Zealand White (NZW) outbred and EIII/JC inbred rabbits were anesthetized with 40mg/kg Ketamine 
and 5mg/kg Xylazine. Rabbit back skin was scarified as reported previously [15]. Three days later, rabbits were 
challenged with viral DNA (5μg DNA/ site). Beginning three weeks after virus or DNA challenge, the rabbits were 
monitored weekly for papilloma development.  
Papilloma size was determined by calculating the cubic root of the product of length × width × height of 
individual papillomas in millimeters to obtain a geometric mean diameter (GMD). Data were represented as the 
means (+ SEMs) of the GMDs for each test group. Statistical significance was determined by unpaired t-test
comparison (P<0.05 was considered significant). The frequency of sites without papillomas was calculated as the 
number of sites without papillomas/total challenged sites. Statistical significance was determined by Fisher’s Exact 
Test (P<0.05 was considered significant).   
3. Results
3.1. CTL generation in HLA-A2.1 transgenic mouse system 
 Using a peptide immunization strategy, two HLA-A2.1 transgenic mice (HHD) were immunized with 
either CRPVE1/161-169 or CRPVE1/303-311 peptide. The spleens were harvested one week after the booster 
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immunization and cultured in vitro with gamma-irradiated peptide-pulsed mouse dendritic cells prepared as 
described[16]. After two in vitro stimulations, the cultured bulk CTLs from HLA-A2.1 transgenic mice were tested 
for the generation of specific CD8 T cells using synthesized tetramers. Both peptide-immunized mice showed a 
significantly increased population of specific tetramer positive CD8 T cells (P<0.05, unpaired student t test, Fig 1A).  
The bulk CTLs were then examined for intracellular interferon gamma (IFNȖ) levels using the same 
protocol reported previously [5]. Mice immunized  with both peptides (CRPVE1/161-169 and 303-311) showed 
significantly increased populations of IFNȖ secreting CD8 T cells when compared to control peptides (P<0.05, 
unpaired student t test, Figure 1B, C). Significantly more IFNȖ secreting CD8 T cells were generated in re-
stimulated cultures from CRPVE1/303-311 immunized mice when compared with those from CRPVE1/161-169 
immunized mice.  
3.2. Protective immunity by CRPVE1/303-311 and CRPVE1/161-169 vaccination in outbred HLA-A2.1 rabbits 
against CRPV DNA infection 
 Next, we wanted to test if these two immunogenic epitopes could stimulate specific protective immunity in 
HLA-A2.1 transgenic rabbits following CRPV challenge. Because of the successful use of DNA vaccination in our 
previous studies, we generated two DNA vaccines expressing each of these two epitopes as described previously [5]. 
Two independent experiments were conducted. After a single booster immunization, the rabbits were challenged 
with wtCRPV and coCRPV at left and right back sites respectively. Tumor development was monitored weekly 
until week 12.  
Two independent experiments were conducted: In the first experiment, four HLA-A2.1 transgenic rabbits were used 
for each group (CRPVE1/161-169, CRPVE1/303-311 and Ub3 control group). One rabbit in the CRPVE1/161-169 
group died prior to DNA challenge. One out of three rabbits in this group was protected while all four rabbits in 
CRPVE1/303-311 group were protected from DNA challenge (Table 1, P=0.051, P<0.001 vs. control group, fisher’s 
exact test). No rabbits from the Ub3 control group were protected (Table 1).  In a repeat second experiment, five 
transgenic rabbits were vaccinated with the CRPVE1/161-169 vaccine and one transgenic rabbit vaccinated with 
CRPVE1/303-311. Four HLA-A2.1 transgenic rabbits were immunized with the HPV16E7/82-90 epitope DNA 
vaccine as specificity controls. All rabbits immunized with either CRPVE1/161-169 or CRPVE1/303-311 epitope 
DNA vaccines were completely protected from both wtCRPV and coCRPV DNA infection while no protection was 
found in the HPV16E7/82-90 epitope DNA vaccine control group. Taken together, both CRPVE1/161-169 and 
CRPVE1/303-311 epitope DNA vaccines provided partial and complete protective immunity in HLA-A2.1 
transgenic rabbits (Table 1, P<0.05, fisher’s Exact Test). 
3.3. Protective immunity to CRPVE1/303-311 and CRPVE1/161-169 vaccination in EIII/JC inbred HLA-A2.1 
rabbits 
We also tested the protective immunity of these two epitope DNA vaccines in HLA-A2.1 transgenic rabbits with an 
EIII/JC inbred genetic background. As expected, strong immunity against both wtCRPV and coCRPV infection was 
induced by CRPVE1/303-311 and CRPVE1/161-169 immunization although no significant difference in tumor free 
sites was found (Table 2, P>0.05, fisher’s Exact Test). However, significant smaller papillomas were found between 
epitope vaccinated rabbits and control rabbits infected with both wtCRPV and coCRPV DNA (P<0.05, unpaired 
student t test, Figure 2A, B).   
3.4. Cross reaction was found in normal ( non HLA A 2.1) EIII/JC inbred rabbits  but not in normal outbred rabbits 
vaccinated with  E1/303-311 DNA  
To investigate whether CRPVE1/303-311 and CRPVE1/161-169 can be additionally presented by the 
EIII/JC inbred rabbit MHCI, 3 groups of 4 normal EIII/JC inbred rabbits were immunized with CRPVE1/303-311, 
CRPVE1/161-169 or HPV16E7/82-90 respectively. One week after the final immunization, the rabbits were 
challenged with wtCRPV and coCRPV at the left and right back sites respectively. The papilloma outgrowth was 
monitored weekly at 3 weeks following DNA challenge. Rabbits immunized with CRPVE1/303-311 grew 
significantly smaller papillomas when compared with those immunized with CRPVE1/161-169 and HPV16E7/82-
90 (Figure 3A, B, P<0.05, unpaired student t test). The papilloma size in CRPVE1/161-169 immunized rabbits was 
comparable to that in the HPV16E7/82-90 epitope DNA immunized rabbits (Figure 3A, B, P>0.05, unpaired student 
t test). Therefore, cross-reactivity was found in HLA-A2.1 transgenic EIII/JC inbred rabbits to the CRPVE1/303-
311 epitope but not to CRPVE1/161-169.  
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CRPVE1/303-311 vaccine was also tested for protection in normal outbred rabbits. In contrast to complete 
protection in HLA-A2.1 transgenic outbred rabbits, no protection was found in normal outbred rabbits vaccinated 
with CRPVE1/303-311. Papilloma size was comparable in these rabbits to papillomas in the HLA-A2.1 transgenic 
rabbits immunized with HPV16E7/82-90 DNA vaccine (Figure 4). These data suggest that the rabbit MHCI allele in 
the inbred rabbit colony was rare or absent in this cohort of outbred rabbits. 
3.5. Therapeutic immunity was induced by CRPVE1/303-311 but not by CRPVE1/161-169 DNA vaccine 
 CRPVE1/303-311 and CRPVE1/161-169 DNA vaccines were also tested for their possible therapeutic 
effect in HLA-A2.1 transgenic rabbits. Eleven HLA-A2.1 transgenic rabbits and eight normal rabbits with outbred 
genetic backgrounds were challenged with wtCRPV DNA and a CRPVE8ATGko mutant [18] at left and right back 
sites. A month following DNA infection, the rabbits were divided into four groups:  six HLA-A2.1 transgenic and 
four normal rabbits were immunized with CRPVE1/303-311 and five HLA-A2.1 transgenic and four normal rabbits 
were immunized with CRPVE1/161-169 and boosted twice at 3-week intervals. The animals were monitored weekly 
and papilloma sizes were recorded. 
 Papillomas induced by wtCRPV DNA on two of the CRPVE1/303-311 epitope vaccinated and one of the 
CRPVE1/161-169  epitope vaccinated HLA-A2.1 transgenic rabbits became smaller or regressed while those on the 
other three became larger. The mean papilloma size on this group of rabbits was significantly smaller when 
compared to that of the other groups (Figure 5A, P <0.05, unpaired student t test).  Similar results were found from 
CRPVE8ATGko mutant induced papillomas (Figure 5B, P <0.05, unpaired student t test). Two out of six rabbits 
were free of papillomas induced by the CRPVE8ATGko genome and one rabbit had three small tumors. The mean 
papilloma size of CRPVE8ATGko- induced papillomas was smaller when compared to the mean size before the 
vaccination treatment although these differences were not statistically different (Figure 5B, P >0.05, unpaired 
student t test).   
 In contrast, papillomas induced by wtCRPV and CRPVE8ATGko in normal rabbits immunized with both 
epitope DNA vaccines grew significantly larger after the therapeutic treatment than those before therapy treatments 
when compared to pre-therapy mean size (Figure 5A, B, P <0.05, unpaired student t test).  
    
4. Discussion 
 In this report, we incorporated studies using HLA-A2.1 transgenic mice with the CRPV / HLA-A2.1 
transgenic rabbit for comparative and complementary analyses and to test for protection in vivo (rabbit model only). 
Two HLA-A2.1 restricted epitopes predicted by online programs (CRPVE1/161-169 and CRPVE1/303-311) and 
identified as immunogenic in the HLA-A2.1 transgenic mice, induced strong protective immunity in HLA-A2.1 
transgenic rabbits. The HLA-A2.1 transgenic mouse model has the advantage of reduced cost and a large panel of 
reagents to test the immunogenicity of potential epitopes [2]. However, the mouse model system does not provide an 
in vivo infection model for papillomaviruses.  In contrast, rabbits can be infected with species-specific 
papillomaviruses as well as several human pathogenic viruses [HTLV-1/2[19], EBV-like virus [20]]and are also 
susceptible hosts for tuberculosis and syphilis [21], [22]. We demonstrated here that our transgenic rabbit model 
system showed good agreement with the mouse model. The HLA-A2.1 transgenic mouse system can thus be used to 
prescreen the immunogenicity profiles of predicted epitopes for further characterization in our in vivo rabbit model. 
Most importantly, our recent work demonstrated that the rabbit papillomavirus (CRPV) genome has a high capacity 
for modification without compromising its ability to induce papillomas in animals [10]. By generating hybrid and 
mutant genomes that are functional in the rabbits, we can test specific immunity of predicted epitopes for additional 
pathogens as well as tumor associated antigens when embedded into the CRPV genome.  
HLA-A2.1 molecules have been shown to co-localize with rabbit MHCI exclusively on transgenic cell 
surfaces [4]. HLA-A2.1 also appears to be expressed at equivalent levels to endogenous rabbit MHCI in our studies. 
Therefore, a possible dual presentation of single epitopes by both the transgene and a rabbit MHCI could complicate 
interpretation of the results. Indeed, in this study, we found that the more immunogenic epitope CRPVE1/303-311 
functioned as a protective epitope in EIII/JC inbred rabbits. EIII/JC inbred rabbits have a  unique MHC molecular 
constitution when compared to that of the outbred rabbits [18, 23-25], and unpublished observations).  Since no 
crystal structure exists for rabbit MHCI molecules, and peptide anchor residues for EIII/JC MHCI molecules are 
uncharacterized, it will be interesting to eventually determine binding motifs of these rabbit MHCI molecules and 
peptides. We can suggest that EIII/JC MHCI and HLA-A2.1 are not identical as no protections were observed in the 
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non-transgenic EIII/JC rabbits when vaccinated with peptide CRPVE1/161-169, but protection occurred in the 
transgenic rabbits.  
 Skin papillomas are usually difficult to resolve and no effective therapeutic vaccine is available to date [9].
It is intriguing that CRPVE1/303-311 showed potential therapeutic effects in HLA-A2.1 transgenic rabbits. 
Although papillomas on only one of the six rabbits regressed, those on one other rabbit became significantly smaller 
after the treatment. Interestingly, a stronger therapeutic effect was found in smaller papillomas induced by 
CRPVE8ATGko when compared with those larger papillomas induced by wtCRPV. This finding is consistent with 
our previous reports using a multivalent DNA vaccine, in which we achieved much stronger therapeutic effects in 
HLA-A2.1 transgenic rabbits [11]. Other studies have demonstrated that rabbits vaccinated with multiple early 
genes achieved the better therapeutic result [26-28].  Therefore, multivalent epitope vaccines may be a desirable 
extension of current therapeutic vaccines.
 In summary, we have presented here a novel pathway that incorporates online software and both HLA-
A2.1 transgenic mouse and rabbit model systems to test the immunogenicity of HLA-A2.1 restricted epitopes in 
vitro and in vivo. Our results demonstrate high consistency of epitope responsiveness between these two animal 
models. We anticipate that the combination of these two systems will prove very useful for the development of both 
protective and therapeutic HPV vaccines [29, 30]. 
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Table 1. Partial and complete protection stimulated by CRPVE1/161-169 and CRPVE1/303-311 epitope DNA 
vaccination in outbred HLA-A2.1 transgenic rabbits 
Rabbits ID Vaccine Papillomas sites Protection sites Protection rates
1118 4 0 0/4 
1203 0 4 4/4 
1204 4 0 0/4 
1294 0 4 4/4 
1299 0 4 4/4 
1300 0 4 4/4 
1301 0 4 4/4 
1314
CRPVE1/161-169 
0 4 4/4 
Total 8 24 24/32 (75%)a
1120 0 4 4/4 
1121 0 4 4/4 
1205 0 4 4/4 
1206 0 4 4/4 
1292
CRPVE1/303-311 
0 4 4/4 
Total 0 20 20/20 (100%) b
1122 4 0 0/4 
1123 4 0 0/4 
1207 2 2 2/4 
1208
HPV16E7/82-90 
4 0 0/4 
Total 14 2 2/16 (12.5%) c
1284 4 0 0/4 
1286 4 0 0/4 
1289 6 0 2/4 
1291
Control Ub3 
4 0 0/4 
Total 16 0 0/16 (0%)
a P<0.05 , b P<0.01, c P>0.05 vs.  Ub3 group respectively, Fisher’s Exact Test 
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Table 2. Protective immunity induced by CRPVE1 epitope DNA vaccination in EIII/JC inbred HLA-A2.1
transgenic rabbits  
Rabbits ID Vaccine Papillomas sites Protection sites Protection rates
825 0 4 4/4 
831 0 4 4/4 
865
CRPVE1/161-169 
2 2 2/4 
Total 2 10 10/12 a
 (83.3%) 
822 0 4 4/4 
833 0 4 4/4 
866
CRPVE1/303-311 
3 1 1/4 
Total 3 9 9/12 b
(75%)
826 0 4 4/4 
857 4 0 0/4 
861
Control Ub3 
4 0 0/4 
Total 8 4 4/12 
 (33.3%) 
a P=0.17 , b P=0.21 vs.  Ub3 group respectively, Fisher’s Exact Test 
Figure 1 
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Both CRPVE1/161-169 and CRPVE1/303-311 peptide immunized mice generated specific tetramer binding CD8 T 
cells that secreting intracellular interferon gamma (IFNȖ) after in vitro culture. The spleen cells harvested from both 
CRPVE1/161-169 and CRPVE1/303-311 peptide immunized mice were stimulated with corresponding peptide 
pulsed mouse dendritic cells twice weekly. These bulk CTLs were then tested for A) tetramer binding and B, C) 
Intracellular IFNr labeling. An significantly increased population of specific CD8 T cells binding to CRPVE1/161-
169 and CRPVE1/303-311 tetramer was found in these mice respectively (P<0.05, unpaired student t test) (A). 
Significantly more IFNȖ secreting CD8 T cells were also found in these two specific epitope (B, C) vaccinated mice 
to corresponding peptide stimulation when compared with a reference peptide (P<0.05, unpaired student t test). 
Figure 2.  
Papilloma outgrowth in HLA-A2.1 transgenic EIII/JC inbred rabbits after CRPVE1/161-169, CRPVE1/303-311 or 
a control DNA vaccination. Three groups of HLA-A2.1 transgenic EIII/JC inbred rabbits (N=3) immunized with 
CRPVE1/161-169, CRPVE1/303-311 or a control DNA twice were challenged with wtCRPV and coCRPV at four 
left and right back sites respectively. Significantly smaller papillomas were found in both E1 epitope DNA 
vaccinated rabbits when compared with those in control DNA vaccinated rabbits challenged with both wtCRPV 
DNA (A) and coCRPV DNA (B) (P<0.01 vs. control group, unpaired student t test). Some challenge sites regressed 
over the time course. No significant difference was found between these two E1 epitope vaccinated rabbits (P>0.05, 
unpaired student t test). 
Figure 3. 
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Papilloma outgrowth in normal EIII/JC inbred rabbits after CRPVE1/303-311 , CRPVE1/161-169 and 
HPV16E7/82-90 epitope DNA vaccination. Four normal EIII/JC inbred rabbits immunized with CRPVE1/303-
311, CRPVE1/161-169 and HPV16E7/82-90 epitope DNA vaccine respectively were challenged with wild type 
CRPV DNA and coCRPV DNA at left and right back sites respectively. Rabbits that immunized with CRPVE1/303-
311 grew significantly smaller papillomas when compared with those immunized with CRPVE1/161-169 and 
HPV16E7/82-90 (P<0.05, unpaired student t test). No significant difference in papilloma size was found between 
CRPVE1/161-169 and HPV16E7/82-90 epitope vaccinated rabbits (P>0.05, unpaired student t test). 
Figure 4.   
Papilloma outgrowth in normal outbred rabbits after CRPVE1/303-311 and HPV16E7/82-90 epitope DNA 
vaccination. Three and four normal outbred rabbits immunized with CRPVE1/303-311 and HPV16E7/82-90 
epitope DNA vaccine respectively were challenged with wild type CRPV DNA. Although a growth delay occurred 
in rabbits that immunized with CRPVE1/303-311 before week 7 after viral DNA challenge, no significant difference 
in papilloma size was found between these two epitope vaccinated rabbits after week 7(P>0.05, unpaired student t 
test).
Figure 5.  
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Therapeutic DNA vaccination in HLA-A2.1 and normal outbred rabbits with CRPVE1/161-169 or CRPVE1/303-
311 epitope DNA vaccination. Four weeks after challenged with wtCRPV and CRPVE8ATGko, eleven HLA-A2.1
(A2) and eight normal outbred (N) rabbits were immunized with CRPVE1/303-311 (6A2/4N)or CRPVE1/161-169 
(5A2/4N) DNA vaccines for three times. CRPVE1/303-311 epitope DNA vaccine slowed down papilloma growth 
induced by both wtCRPV DNA (A) and CRPVE8ATGko DNA (B) in HLA-A2.1 transgenic rabbits significantly 
when compared with the three other groups of vaccinated rabbits (P<0.05 vs. control groups, unpaired student t test). 
No significant difference was found among the HLA-A2.1 rabbits vaccinated with CRPVE1/161-169 or normal 
rabbits vaccinated with CRPVE1/161-169 or CRPVE1/303-311(P>0.05, unpaired student t test). 
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